Histopathological verification of glioblastoma multiforme (GBM: WHO grade IV) in remission (Group A) or with active disease (Group B). 
CMV-positive GBM 
CMV seropositive 
Life expectancy 6 weeks or greater 
Karnofsky/Lansky score 50 or greater 
Patient or parent/guardian capable of providing informed consent 
Bilirubin less than 1.5x upper limit of normal, AST less than 3x upper limit of normal, serum creatinine less than 1.5x normal and Hgb 8.0 g/dL or greater 
Pulse oximetry of 90% or greater on room air 
Sexually active patients must be willing to utilize one of the more effective birth control methods for 6 months after the CTL infusion. The male partner should use a condom. 
Patients should have been off other investigational antineoplastic therapy for one month prior to entry in this study. 
Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent. 

NCT01205334_inc_T1
Condition
glioblastoma multiforme
NCT01205334_inc_T2
Procedure
Histopathological
NCT01205334_inc_T3
Observation
Histopathological verification
NCT01205334_inc_T4
Measurement
WHO
NCT01205334_inc_T5
Value
grade IV
NCT01205334_inc_T6
Qualifier
in remission
NCT01205334_inc_T7
Qualifier
Group A
NCT01205334_inc_T8
Qualifier
Group B
NCT01205334_inc_T9
Temporal
active
NCT01205334_inc_T10
Qualifier
with active disease
NCT01205334_inc_T11
Scope
in remission (Group A) or with active disease (Group B)
NCT01205334_inc_T12
Qualifier
CMV-positive
NCT01205334_inc_T13
Condition
GBM
NCT01205334_inc_T14
Condition
GBM
NCT01205334_inc_T15
Condition
CMV
NCT01205334_inc_T16
Condition
CMV seropositive
NCT01205334_inc_T17
Observation
Life expectancy
NCT01205334_inc_T18
Value
6 weeks or greater
NCT01205334_inc_T19
Measurement
Karnofsky/Lansky
NCT01205334_inc_T20
Value
score 50 or greater
NCT01205334_inc_T22
Measurement
Bilirubin
NCT01205334_inc_T23
Value
less than 1.5x upper limit of normal
NCT01205334_inc_T24
Measurement
AST
NCT01205334_inc_T25
Value
less than 3x upper limit of normal
NCT01205334_inc_T26
Measurement
Pulse oximetry
NCT01205334_inc_T27
Value
90% or greater
NCT01205334_inc_T28
Qualifier
on room air
NCT01205334_inc_T31
Procedure
antineoplastic therapy
NCT01205334_inc_T32
Negation
been off
NCT01205334_inc_T33
Temporal
for one month prior to entry in this study
NCT01205334_inc_T34
Reference_point
entry in this study